24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Chiasma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:32
Why Monday.com’s impressive revenue jump wasn’t enough for Wall Street
14:52
"We have a bitcoin president!" The real winner in the US election
12:59
Pandemic high to deep decline: How LivePerson’s valuation dropped from $4.7B to $60M
12:00
Viola Ventures' next fund to be led by Zvika Orron and Omry Ben David, together with founder Shlomo Dovrat
More stories
Buzz
Most popular
Daily
Weekly
1
$100M in savings not enough to justify Intel’s coffee cut
2
Cyber startup Upwind raising $100 million at $850-900M valuation
3
Viola Ventures' next fund to be led by Zvika Orron and Omry Ben David, together with founder Shlomo Dovrat
4
CrowdStrike acquires Adaptive Shield in $300M deal to boost SaaS security
5
Why Monday.com’s impressive revenue jump wasn’t enough for Wall Street
More news
Chiasma
1 stories about Chiasma
Nasdaq-Listed Biopharma Company Chiasma Raises $34.5 Million in Public Offering
09.04.19
|
CTech
Chiasma develops octreotide capsules for the treatment of acromegaly, a rare, chronic disease typically caused by a benign tumor of the pituitary gland
Please ensure Javascript is enabled for purposes of
website accessibility